Estimating the cost-effectiveness of screening a general population for cardiovascular risk with high-sensitivity troponin-I.

ABSTRACT:

Aims

To estimate the cost-effectiveness of using the cardiac specific marker high-sensitivity troponin-I (hsTnI) for assessing cardiovascular disease (CVD) risk in a general population.

Methods and results

A discrete-event simulation model was developed from a societal perspective of a low-risk (Germany) and a high-risk (Kazakhstan) country. The model compared a Screen&Prevent strategy guided by hsTnI against a do-nothing strategy. Risk functions were derived from published data of a prospective cohort study [Nord-Trøndelag Health (HUNT) Study]. The model assessed the number of CVD events and deaths, healthy life years, direct and indirect costs in PPP 2018 Dollar, and quality-adjusted life years (QALY) over a time horizon of 10 years. Screen&Prevent reduced the number of CV

SUBMITTER: Julicher P 

PROVIDER: S-EPMC9071558 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature